Merck & Co INC (MRK) Shareholder Healthcor Management LP Lifted Holding

May 18, 2018 - By Adrian Mccoy

Merck & Co., Inc. (NYSE:MRK) LogoInvestors sentiment decreased to 0.94 in 2017 Q4. Its down 0.12, from 1.06 in 2017Q3. It worsened, as 94 investors sold MRK shares while 631 reduced holdings. 123 funds opened positions while 558 raised stakes. 1.93 billion shares or 1.34% less from 1.96 billion shares in 2017Q3 were reported. Lenox Wealth Management reported 1,738 shares stake. Private Ocean Limited Liability Co holds 0.05% or 1,720 shares in its portfolio. Highstreet Asset Management reported 20,179 shares or 0.07% of all its holdings. Wilbanks Smith & Thomas Asset Limited Co reported 0.38% in Merck & Co., Inc. (NYSE:MRK). Next Fincl Grp holds 13,138 shares or 0.32% of its portfolio. Windsor Cap Mngmt Limited Liability Corporation stated it has 8,895 shares or 0.23% of all its holdings. Beach Counsel Pa reported 0.43% stake. New York-based Sg Americas Ltd Llc has invested 0.27% in Merck & Co., Inc. (NYSE:MRK). North Star Asset Management Incorporated stated it has 0.06% in Merck & Co., Inc. (NYSE:MRK). Glg Partners Lp holds 1,863 shares. Private Wealth Limited Company has invested 2.62% in Merck & Co., Inc. (NYSE:MRK). Veritas Mgmt (Uk) Limited owns 3,260 shares. X Mgmt Ltd Com owns 7,519 shares. Murphy Pohlad Asset Mgmt Ltd Liability Company reported 12,358 shares. Palisades Hudson Asset Mngmt Ltd Partnership holds 3,822 shares or 0.12% of its portfolio.

Arthur B Cohen increased its stake in Merck & Co Inc (MRK) by 464.17% based on its latest 2017Q4 regulatory filing with the SEC. Healthcor Management Lp bought 3.21 million shares as the company’s stock declined 4.63% with the market. The hedge fund run by Arthur B Cohen held 3.90 million shares of the health care company at the end of 2017Q4, valued at $219.45 million, up from 691,280 at the end of the previous reported quarter. Healthcor Management Lp who had been investing in Merck & Co Inc for a number of months, seems to be bullish on the $159.28B market cap company. The stock increased 0.23% or $0.14 during the last trading session, reaching $59.21. About 798,058 shares traded. Merck & Co., Inc. (NYSE:MRK) has declined 14.94% since May 18, 2017 and is downtrending. It has underperformed by 26.49% the S&P500.

Healthcor Management Lp, which manages about $3.20 billion and $3.07B US Long portfolio, decreased its stake in Boston Scientific Corp (NYSE:BSX) by 319,338 shares to 367,832 shares, valued at $9.12 million in 2017Q4, according to the filing. It also reduced its holding in Danaher Corp Del (NYSE:DHR) by 1.13M shares in the quarter, leaving it with 124,660 shares, and cut its stake in Bioverativ Inc.

More notable recent Merck & Co., Inc. (NYSE:MRK) news were published by: which released: “FDA Lists Brand-Name Drugmakers That Obstruct Generic Development” on May 18, 2018, also with their article: “Better Buy: Pfizer Inc. (PFE) vs. Merck (MRK)” published on May 13, 2018, published: “Morgan Finds Positive Datapoints For MRK and BMY At ASCO” on May 17, 2018. More interesting news about Merck & Co., Inc. (NYSE:MRK) were released by: and their article: “Merck & Co., Inc. (NYSE:MRK) Trending Upwards” published on May 18, 2018 as well as‘s news article titled: “Merck: Getting Stronger” with publication date: May 04, 2018.

Merck & Co., Inc. (NYSE:MRK) Ratings Coverage

Among 13 analysts covering Merck & Company (NYSE:MRK), 10 have Buy rating, 0 Sell and 3 Hold. Therefore 77% are positive. Merck & Company had 21 analyst reports since November 24, 2017 according to SRatingsIntel. DZ Bank upgraded Merck & Co., Inc. (NYSE:MRK) on Tuesday, February 13 to “Buy” rating. Jefferies maintained it with “Hold” rating and $5600 target in Friday, April 13 report. The rating was maintained by Jefferies on Tuesday, January 16 with “Hold”. The stock of Merck & Co., Inc. (NYSE:MRK) earned “Overweight” rating by Morgan Stanley on Tuesday, April 17. The rating was maintained by Credit Suisse on Monday, February 5 with “Outperform”. The company was maintained on Wednesday, February 14 by BMO Capital Markets. The firm has “Hold” rating given on Friday, March 23 by Jefferies. Leerink Swann upgraded Merck & Co., Inc. (NYSE:MRK) rating on Monday, March 12. Leerink Swann has “Buy” rating and $66.0 target. The firm has “Outperform” rating by BMO Capital Markets given on Thursday, April 26. The rating was maintained by Morgan Stanley on Wednesday, February 7 with “Equal-Weight”.

Merck & Co., Inc. (NYSE:MRK) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.